ClinicalTrials.gg
CompletedNCT03462108Updated Apr 3, 2019

Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates

A Phase 1 interventional study of Rotavirus (Bio Farma) Vaccine and Placebo in Safety Issues, sponsored by PT Bio Farma. Completed at 4 sites in Indonesia. Open to participants aged 1 Minute to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-03.

Sponsored by PT Bio Farma · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
1 Minute to 40 Years
Sex
All
01

Study summary

This study is to assess the safety of Rotavirus (Bio Farma) vaccine in adults, children and neonates.

Read the detailed description

To describe the safety of this vaccine after each immunization. To assess preliminary information of immunogenicity following Rotavirus (Bio Farma) vaccine immunization.

02

Conditions studied

  • Safety Issues
03

In context

Lead sponsor

PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Adults:

  • Healthy Adults as determined by clinical judgment, including a medical history, physical exam and laboratory results, which confirms the absence of a current or past disease state considered significant by the investigator.
  • Subjects have been informed properly regarding the study and signed the form.
  • Subject will commit to comply with the instructions of the investigator and the schedule of the trial.

Inclusion Criteria for Children:

  • Healthy Children as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator.
  • Parents/guardian(s) have been informed properly regarding the study and signed the informed consent form
  • Parent/guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.

Inclusion Criteria for Neonates:

  • Neonate 0-5 days of age at the time of first dose, with cord blood available
  • Neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator.
  • The neonate was born full term (minimum of 36 completed weeks and maximum of 42 completed weeks gestation).
  • Neonate birth weight 2500-4000 g inclusive.
  • Parents or guardians have been informed properly regarding the study and signed the informed consent form
  • Parents or guardians will commit to comply with the instructions of the investigator and the schedule of the trial

Exclusion Criteria for Adults:

  • Subject concomitantly enrolled or scheduled to be enrolled in another trial
  • Any direct relatives relationship with the study team.
  • Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.
  • Known history of allergy to any component of the vaccines
  • Known history of immunodeficiency disorder ( infection, leukemia, lymphoma, or )
  • Gastroenteritis in the 24 hours preceding enrollment.
  • History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
  • Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or therapy and other immunosuppresant).
  • Subject consuming or expect to consume a probiotics within one week before and after vaccination
  • Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
  • Pregnancy \& lactation (Adults).
  • Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.
  • Subject planning to move from the study area before the end of study period.

Exclusion Criteria for Children:

  • Subject concomitantly enrolled or scheduled to be enrolled in another trial
  • Any direct relatives relationship with the study team
  • Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C ) within the 48 hours preceding enrollment
  • Known history of allergy to any component of the vaccines
  • Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or malignancy)
  • Gastroenteritis in the 24 hours preceding enrollment.
  • Any history of chronic gastrointestinal disease including uncorrected congenital malformation of gastrointestinal tract that would predispose for Intusussception.
  • History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
  • Subject who has received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or corticosteroid therapy and other immunosuppresant).
  • Subjects consuming or expect to consume a probiotics within one week before and after vaccination.
  • Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
  • Individuals who have previously received any rotavirus vaccine.
  • Subject already immunized with any vaccine within 4 weeks prior and expects to receive other vaccines within 4 weeks following immunization.
  • Subject planning to move from the study area before the end of study period

Exclusion Criteria for Neonates:

  • Subject concomitantly enrolled or scheduled to be enrolled in another trial.
  • Any direct relatives relationship with the study team.
  • Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature ³ 37.5°C) within the 48 hours preceding enrollment.
  • Subject with known or suspected history of allergy to any component of the vaccines.
  • Subject with a biological mother with a known or suspected human immunodeficiency virus (HIV) infection.
  • Subject with known or suspected major congenital malformations or genetically determined disease.
  • Subject with intussusception.
  • Subject with a known or suspected disease of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
  • Subject with a known or suspected disease of the immune system or those who has received immunosuppresive therapy, including immunosuppresive courses of systemic corticosteroid.
  • Subject who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product during the course of study.
  • Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.
  • Subject immunized with non- EPI vaccines.
  • Gastroenteritis in the 24 hours preceding enrollment.
  • Subject planning to move from the study area before the end of study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Rotavirus (Bio Farma) Vaccine-Adult

    1 doses of 1 ml of Rotavirus vaccine per oral

    Biological: Rotavirus (Bio Farma) Vaccine

  • Experimental
    Rotavirus (Bio Farma) Vaccine-Children

    1 doses of 1 ml of Rotavirus vaccine per oral

    Biological: Rotavirus (Bio Farma) Vaccine

  • Experimental
    Rotavirus (Bio Farma) Vaccine-Neonates

    3 doses of 1 ml of Rotavirus vaccine per oral

    Biological: Rotavirus (Bio Farma) Vaccine

  • Placebo comparator
    Placebo-Neonates

    3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral

    Other: Placebo

Interventions

  • BiologicalRotavirus (Bio Farma) Vaccine

    Rotavirus (Bio Farma) Vaccine

  • OtherPlacebo

    Placebo contains 30% sucrose in DMEM

06

What researchers measure

Primary outcomes

  1. Solicited symptoms after each immunization

    Number of subjects with solicited systemic and gastrointestinal symptoms in the day 0-7 following each dose of investigational product

    Time frame: 0-7 days

Secondary outcomes

  1. Adverse events of Rotavirus (Bio Farma) vaccine

    Number and percentage of subjects with unsolicited Adverse Events (AE) in the day 0-28 following each dose of investigational product

    Time frame: 28 days

  2. Serious adverse events of Rotavirus (Bio Farma) vaccine

    Number and percentage of subjects with Serious Adverse Events (SAE) within 28 days after each dose of investigational product

    Time frame: 28 days

  3. Adverse events of Rotavirus (Bio Farma) vaccine compare to placebo in neonates group

    Number and percentage of subject with adverse event (AE) within 28 days after each dose of investigational product compare to placebo (in neonates group)

    Time frame: 28 days

  4. Serious adverse events of Rotavirus (Bio Farma) vaccine compare to placebo in neonates group

    Number and percentage of subject with Serious Adverse Events (SAE) within 28 days after each dose of investigational product compare to placebo (in neonates group)

    Time frame: 28 days

  5. Number of subject who has abnormality value of routine hematology and biochemical evaluation that probably related to the vaccination

    Deviation in routine hematology and biochemical evaluation

    Time frame: 7 days

  6. Excretion of rotavirus in stools in neonates group

    Number of neonates with rotavirus excretion in stools

    Time frame: 3-7 days

  7. Number of subjects with >=3 times increasing antibody from baseline to post investigational product dosing

    Subjects with \>=3 times increasing antibody from baseline to post investigational product dosing

    Time frame: 4-6 weeks after last immunization

  8. Serum anti-rotavirus immunoglobulin (Ig)A following immunization

    Serum anti-rotavirus immunoglobulin (Ig)A before and after last immunization

    Time frame: 4-6 weeks after last immunization

  9. Serum neutralizing antibody (SNA) following immunization

    Serum neutralizing antibody (SNA) before and after last immunization

    Time frame: 4-6 weeks after last immunization

  10. Geometric Mean Titer (GMT) following immunization

    Geometric mean titer (GMT) before and after last immunization

    Time frame: 4-6 weeks after last immunization

07

Study locations

4 sites
  • Gantiwarno Primary Health Center
    Klaten, Central Java, Indonesia
  • Klaten Selatan Primary Health Center
    Klaten, Central Java, Indonesia
  • Ngawen Primary Health Center
    Klaten, Central Java, Indonesia
  • RS Soeradji Tritonegoro
    Klaten, Central Java, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Feb 2019, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Mar 12, 2018
StartActual
Apr 9, 2018
Primary completionActual
Feb 18, 2019
CompletionActual
Mar 30, 2019
Last update
Apr 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03462108
Lead sponsor
PT Bio Farma
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Apr 9, 2018
Primary completion
Feb 18, 2019
Completion
Mar 30, 2019
Last update
Apr 3, 2019

Study contacts

Jarir At Thobari
principal investigator · Pediatric Research Office (PRO), Departemen Ilmu Kesehatan Anak, Fakultas Kedokteran UGM/RSUP Dr. Sardjito

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion